IMMUNOBIOGRAM PHARMACOECONOMIC MODEL IN KIDNEY TRANSPLANTATION

Inadequate immunosuppression treatment in kidney transplant patients can lead to graft failure, resulting in significant direct costs and a decrease in the patient’s quality of life due to the increased risk of requiring dialysis or retransplantation.

The Immunobiogram enables healthcare professionals to personalize immunosuppressive treatment for each patient, preventing graft failure or adverse events, and resulting significant cost savings for healthcare systems, as our published pharmacoeconomic model demonstrates.

Patients with HIGH RISK of graft rejection

€0
Savings of costs per patient
0
Years
0%
Saving probability

For stable, low risk patients, the use of the IMBG would entail an expected reduction in the adverse events rate with savings of € 1,419 per patient in 5 years, and a 97,7% saving probability.

Patients with LOW RISK of graft rejection

€0
Savings of costs per patient
0
Years
0%
Saving probability

Therefore, the routinely use of the Immunobiogram in patients one year after their kidney transplant may have considerable savings for the Spanish NHS.